Share this article
Free Whitepaper
Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States
Cell and gene therapies (CGT) have seen expansive clinical development and revenue growth over the past 5 years across various therapeutic areas. Â
With the approval of 12 new therapies and the initiation of over 2,900 clinical trials between the analysis period of 2016 -2021, it is evident there is extensive investment in the innovation of CGT. Notably, oncology is the leading therapeutic area, with the highest percentage of new clinical development year-on year compared to other CGT therapy areas, indicating a high level of unmet needs and increased industry investment in the space.Â
Access GlobalData’s new whitepaper, Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States to gain a better understanding of the developments, challenges and opportunities in CGT including exclusive insights on promising future oncology CGT assets in development. Â
The white paper covers:Â
- The key takeaways of cell and gene therapy Â
- Extensive background on the uptake of cell and gene therapy Â
- Insights and outlook of cell and gene therapy trials in the USÂ Â
- An analysis of the top oncology cell and gene therapy assets and developersÂ
Thank you.
You will receive an email shortly. Please check for download the Whitepaper.
Free Whitepaper
Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States
Cell and gene therapies (CGT) have seen expansive clinical development and revenue growth over the past 5 years across various therapeutic areas. Â
With the approval of 12 new therapies and the initiation of over 2,900 clinical trials between the analysis period of 2016 -2021, it is evident there is extensive investment in the innovation of CGT. Notably, oncology is the leading therapeutic area, with the highest percentage of new clinical development year-on year compared to other CGT therapy areas, indicating a high level of unmet needs and increased industry investment in the space.Â
Access GlobalData’s new whitepaper, Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States to gain a better understanding of the developments, challenges and opportunities in CGT including exclusive insights on promising future oncology CGT assets in development. Â
The white paper covers:Â
By GD50 Custom
- The key takeaways of cell and gene therapy Â
- Extensive background on the uptake of cell and gene therapy Â
- Insights and outlook of cell and gene therapy trials in the USÂ Â
- An analysis of the top oncology cell and gene therapy assets and developersÂ
Thank you.
You will receive an email shortly. Please check for download the Whitepaper.
Go deeper with GlobalData
Related Company Profiles
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.